Optimizing Treatment of Follicular Lymphoma : Episode 9

The DYNAMO Later-Line Regimen

Jan 28, 2020

Transcript:

Related Videos

Eunice Wang, MD

Expert on DLBCL

Tycel Phillips, MD

Expert on ALL

Michael Andreeff, MD, PhD

Brian C. Ball, MD

Mitchell E. Horwitz, MD

Bradley W. Christensen, MD

Jorge E. Cortes, MD

Bradley W. Christensen, MD

Related Content

Quizartinib Garners Approval in Japan for Newly Diagnosed FLT3-ITD+ AML

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

OncLive Honors 12 Cancer Care Pioneers

FDA Approval Insights: Zanubrutinib in CLL and SLL

February 16th 2023

Chinese Phase 3 Trial of Roxadustat in Non-Myeloid Malignancies Meets Primary End Point

Epcoritamab Could Provide Active and Accessible Treatment Option for R/R LBCL

Quizartinib Garners Approval in Japan for Newly Diagnosed FLT3-ITD+ AML

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

OncLive Honors 12 Cancer Care Pioneers

FDA Approval Insights: Zanubrutinib in CLL and SLL

February 16th 2023

Chinese Phase 3 Trial of Roxadustat in Non-Myeloid Malignancies Meets Primary End Point

Epcoritamab Could Provide Active and Accessible Treatment Option for R/R LBCL

Quizartinib Garners Approval in Japan for Newly Diagnosed FLT3-ITD+ AML

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

OncLive Honors 12 Cancer Care Pioneers

FDA Approval Insights: Zanubrutinib in CLL and SLL

February 16th 2023

Chinese Phase 3 Trial of Roxadustat in Non-Myeloid Malignancies Meets Primary End Point

Epcoritamab Could Provide Active and Accessible Treatment Option for R/R LBCL

Related Content

Wataru Takasaki, PhD

Quizartinib Garners Approval in Japan for Newly Diagnosed FLT3-ITD+ AML

Mitchell E. Horwitz, MD

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

Ann H. Partridge, MD, MPH

OncLive Honors 12 Cancer Care Pioneers

Ian Flinn, MD, PhD; Nicole Lamanna, MD; Jennifer R. Brown, MD, PhD; Constantine Tam, MD, MBBS

FDA Approval Insights: Zanubrutinib in CLL and SLL

February 16th 2023

Chinese Phase 3 Trial of Roxadustat in Non-Myeloid Malignancies Meets Primary End Point

Chinese Phase 3 Trial of Roxadustat in Non-Myeloid Malignancies Meets Primary End Point

Chan Cheah, MBBS, FRACP, FRCPA, DMSc

Epcoritamab Could Provide Active and Accessible Treatment Option for R/R LBCL

Latest Conference Coverage

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors

Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer

Minimally Invasive Distal Pancreatectomy Provides Effective Alternative in Resectable Pancreatic Cancer

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.